Replies to post #217038 on Biotech Values

[ghmm]

NKTR:

I don't know the credibility of the story if its just another one of these false rumors or not.

Robins has been known to sell at the peak (assets and companies) and they definitely need cash I believe they have more debt than cash right now. Cash is in the 350M range, a pittance considering market cap and how broadly they want to study 214 this year. I had thought Robin would raise money by now even if he is partnering 181 and hoping to get a larger upfront.

I don't know if your familiar with the TKT situation. The company was NOT for sale when they went shopping their EPO program. CEO was so upset he resigned over it.

[DewDiligence]

NKTR—Why the heck would their management consider selling the company now?! Doesn't ring true to me.

They may simply think the stock is overvalued.